MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.clim.2023.109321

Медицинская библиотека · Clinical immunology (Orlando, Fla.) · 2023

Serum soluble mediators as prognostic biomarkers for morbidity, disease outcome, and late-relapsing hepatitis in yellow fever patients.

Fradico Jordana Rodrigues Barbosa, Campi-Azevedo Ana Carolina, Speziali Elaine, do Valle Antonelli Lis Ribeiro, Peruhype-Magalhães Vanessa, de Rezende Izabela Maurício, Alves Pedro Augusto, Pascoal-Xavier Marcelo Antônio, Pereira Leonardo Soares, Dutra Maria Rita Teixeira, Ramalho Dario Brock, Cenachi Adriana, de Paula Ludmila, Santos Tayrine Araujo, do Carmo Said Rodrigo Fabiano, Calzavara-Silva Carlos Eduardo, Coelho-Dos-Reis Jordana Grazziela Alves, de Magalhães Clara Ramos, Rabelo Lara Luíza Cerávolo, Valim Valéria, Brito-de-Sousa Joaquim Pedro, da Costa-Rocha Ismael Artur, de Souza Gomes Matheus, Amaral Laurence Rodrigues, de Lima Sheila Maria Barbosa, Trindade Gisela Freitas, Santos Renata Tourinho, da Silva Juliana Fernandes Amorim, Monath Thomas, LaBeaud Angelle Desiree, Drumond Betânia Paiva, Martins-Filho Olindo Assis, Teixeira-Carvalho Andréa, Yellow Fever Collaborative Group

СтатьяПоддержка NIH: внешняя программаПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

This study described a soluble mediator storm in acute Yellow Fever/YF infection along the kinetics timeline towards convalescent disease. The analyses of the YF Viral RNAnemia, chemokines, cytokines, and growth factors were performed in YF patients at acute/(D1-15) and convalescent/(D16-315) phases. Patients with acute YF infection displayed a trimodal viremia profile spreading along D3, D6, and D8-14. A massive storm of mediators was observed in acute YF. Higher levels of mediators were observed in YF with higher morbidity scores, patients under intensive care, and those progressing to death than in YF patients who progress to late-relapsing hepatitis/L-Hep. A unimodal peak of biomarkers around D4-6 with a progressive decrease towards D181-315 was observed in non-L-Hep patients, while a bimodal pattern with a second peak around D61-90 was associated with L-Hep. This study provided a comprehensive landscape of evidence that distinct immune responses drive pathogenesis, disease progression, and L-Hep in YF patients.

Для цитирования: Fradico Jordana Rodrigues Barbosa, Campi-Azevedo Ana Carolina, Speziali Elaine, do Valle Antonelli Lis Ribeiro, Peruhype-Magalhães Vanessa, de Rezende Izabela Maurício, Alves Pedro Augusto, Pascoal-Xavier Marcelo Antônio, Pereira Leonardo Soares, Dutra Maria Rita Teixeira, Ramalho Dario Brock, Cenachi Adriana, de Paula Ludmila, Santos Tayrine Araujo, do Carmo Said Rodrigo Fabiano, Calzavara-Silva Carlos Eduardo, Coelho-Dos-Reis Jordana Grazziela Alves, de Magalhães Clara Ramos, Rabelo Lara Luíza Cerávolo, Valim Valéria, Brito-de-Sousa Joaquim Pedro, da Costa-Rocha Ismael Artur, de Souza Gomes Matheus, Amaral Laurence Rodrigues, de Lima Sheila Maria Barbosa, Trindade Gisela Freitas, Santos Renata Tourinho, da Silva Juliana Fernandes Amorim, Monath Thomas, LaBeaud Angelle Desiree, Drumond Betânia Paiva, Martins-Filho Olindo Assis, Teixeira-Carvalho Andréa, Yellow Fever Collaborative Group. Serum soluble mediators as prognostic biomarkers for morbidity, disease outcome, and late-relapsing hepatitis in yellow fever patients.. Clinical immunology (Orlando, Fla.). 2023. DOI: 10.1016/j.clim.2023.109321.

Предметные рубрики MeSH

HumansYellow FeverPrognosisCytokinesBiomarkersHepatitisYellow Fever Vaccine
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.